急性缺血性脑卒中患者治疗前后血清S100B蛋白变化及其意义  

Changes and clinical significance of serum protein S100B in acute ischemic cerebral apoplexy patients before and after treatment

作　　者：王幸 曹亚芹[2] 谢全社 王建亭 史景柏 

机构地区：[1]河南扶沟县人民医院内科,扶沟461300 [2]兰州大学临床医学院,兰州730030

出　　处：《中国实用神经疾病杂志》2008年第2期41-42,共2页Chinese Journal of Practical Nervous Diseases

摘　　要：目的探讨急性缺血性脑卒中患者治疗前后血清S100B蛋白的变化及其临床意义。方法采用ELISA法检测86例急性缺血性脑卒中患者治疗前后及46例正常人的血清S100B蛋白水平。结果急性缺血性脑卒中患者治疗前的血清S100B蛋白水平显著高于对照组(P<0.001),差异有统计学意义;急性缺血性脑卒中患者治疗后血清S100B蛋白水平显著下降(P<0.001),差异有统计学意义。结论急性缺血性脑卒中发生时,患者血清S100B蛋白增高;治疗后检测急性缺血性脑卒中患者血清S100B蛋白水平有助于早期诊断、指导治疗及判断预后。Objective To investigate the changes of serum protein S100B of acute ischemic cerebral apoplexy patients before and after treatment and its clinical significance. Methods The level of serum protein S100B of 46 normal subjects and 80 cases of acute ischemic cerebral apoplexy patients before and after treatment were detected by ELISA. Results The level of serum protein S100B in acute ischemic cerebral apoplexy patients group before treatment were higher than control group significantly （P〈0. 001）, the difference was statistically significant. The level of serum protein S100B decreased significantly （P〈0. 001）in acute ischemic cerebral apoplexy patients after treatment, the difference was statistically significant. Conclusion The level of serum protein S100B increases in acute ischemic cerebral apoplexy patients. Detecting the level of serum protein S100B in acute ischemic cerebral apoplexy patients after treatment is helpful to diagnosis early, to guiding therapy and to judging the prognosis for acute ischemic cerebral apoplexy.

关 键 词：急性缺血性脑卒中 S100蛋白 S100B蛋白 血清 

分 类 号：R743.3[医药卫生—神经病学与精神病学]